Key facts about Acute myeloid leukemia (AML)

150 000
New patients per annum globally

Our solution

They support us

Meet the team

Chief Executive Officer 
Jean-Emmanuel SARRY
Chief Scientific Officer 
Christian RECHER
Chief Medical Officer 
Please reach out to us at or use the form
© Copyright 2023 Adreogen

Our mission is to develop innovative therapies that prevent drug resistance, improving cancer patient outcomes

Addressing drug resistance in oncology

Your privacy is very important to us. We will collect and use personal information solely with the objective of responding to your online request.

To improve AML patient outcomes we are are developing therapies that specifically target Relapse-Initiating Cells (RICs), to prevent drug resistance and relapse.
Adreogen is a spin-off from Inserm (National Institute of Health and Medical Research), based in Toulouse, France.

Need more information ?

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It is the most common type of acute leukemia in adults . AML has a poor prognosis due to a high refractory and relapse rate, as leukemic cells become resistant to existing treatments.

< 30%
5-year survival rate
Average age at diagnosis

We are hiring our R&D Director

Job description on LinkedIn

Join us! We are looking for a  motivated and talented person  with a strong background in ImmunoOncology